A prespecified analysis showed benefit with anselamimab in patients with kappa light chain AL amyloidosis.
|Videos|September 21, 2017
Dr. Young Discusses Thromboembolic Events in Pediatric Cancer
Author(s)Guy Young, MD
Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses the occurrence of thromboembolic events in pediatric cancer.
Advertisement
Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses the occurrence of thromboembolic events in pediatric cancer.
Advertisement
Related to this article
The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.
Mipletamig plus venetoclax and azacitidine produced a CBR of 93% in induction-ineligible, TP53-mutated acute myeloid leukemia.
Signatera assay ctDNA testing showed stronger prognostic and predictive value than PET/CT imaging across lymphomas.
Pegylated G-CSF produced rates of successful CD34-positive cell collection and safety comparable to daily G-CSF in healthy allogeneic transplant donors.
The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.
Advertisement
Advertisement
Trending on OncLive
1
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
2
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
3
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
4
Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera
5